TET Systems and Novo Nordisk enter licence agreement
This article was originally published in Scrip
Executive Summary
TET Systems, a Heidelberg, Germany-based company focused on controlled gene expression, has entered into a licence agreement with Novo Nordisk, which allows the latter's Hagedorn Research Institute to use TET's gene expression control Tet technology for its internal research activities. Financial terms of the deal were not disclosed.